Granted Patent
B2
US 7,803,931 · App. 11/058,134 · Granted Sep 28, 2010
Aptamer therapeutics useful in the treatment of complement-related disorders
Assignee:
Archemix Corp.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
Claims (5)
1. A compound consisting of the nucleotide sequence according to SEQ ID NO: 4 and having a PEG polymer of 40 kDa conjugated via a linker to the nucleotide sequence's 5′ end.
2. A compound having the PEGylated aptamer according to SEQ ID NO: 65.
3. A composition comprising a therapeutically effective amount of the compound of claim 1 or 2 or a salt thereof.
4. The composition of claim 3 comprising a pharmaceutically acceptable carrier or diluent.
5. The compound of claim 1 , wherein the PEG polymer of 40 kDa is a branched PEG polymer of 40 kDa.
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 7, 2023
From: ARCHEMIX LLC
To: IVERIC BIO., INC.
Reel/Frame 064833/0421 →
RELEASE OF SECURITY INTEREST
Recorded Jul 17, 2023
From: HERCULES CAPITAL, INC.
To: IVERIC BIO, INC.; IVERIC BIO GENE THERAPY LLC; ORION OPHTHALMOLOGY LLC
Reel/Frame 064286/0472 →
SECURITY INTEREST
Recorded Aug 5, 2022
From: IVERIC BIO, INC.
To: HERCULES CAPITAL, INC.
Reel/Frame 061088/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 30, 2005
From: BENEDICT, CLAUDE; DIENER, JOHN; EPSTEIN, DAVID; GRATE, DILARA; KEENE, SARA CHESWORTH; KURZ, JEFFREY; KURZ, MARKUS; MCCAULEY, THOMAS GREENE; ROTTMAN, JAMES; WILSON, CHARLES; ZOLTOSKI, ANNA J.; THOMPSON, KRISTIN
To: ARCHEMIX CORPORATION
Reel/Frame 017043/0556 →
Continuity (5)
Provisional Application
6054454200
· Feb 12, 2004
Provisional Application
6054774700
· Feb 25, 2004
Provisional Application
6058168500
· Jun 21, 2004
Provisional Application
6060804800
· Sep 7, 2004